galectina-3 e terapia de ressincronização cardíaca

The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression...

Full description

Saved in:
Bibliographic Details
Main Author PIETER MUNTENDAM
Format Patent
LanguagePortuguese
Published 22.11.2016
Subjects
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.
Bibliography:Application Number: BR20121108063